102650-30-6 Usage
General Description
The chemical 1-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid, also known as 1-(p-isothiocyanatobenzyl) DTPA, is a chelating agent commonly used in the field of radiopharmaceuticals and medical imaging. It has a high affinity for metal ions such as copper, gallium, and indium, making it useful for the labeling of proteins and peptides for targeted imaging and therapy. The isothiocyanate group allows for the conjugation of the DTPA molecule to biomolecules, while the diethylenetriaminepentaacetic acid (DTPA) moiety forms stable complexes with metal ions, aiding in their delivery to specific tissues. Its unique structure and properties make it an important component in the development of diagnostic and therapeutic agents for various medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 102650-30-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,2,6,5 and 0 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 102650-30:
(8*1)+(7*0)+(6*2)+(5*6)+(4*5)+(3*0)+(2*3)+(1*0)=76
76 % 10 = 6
So 102650-30-6 is a valid CAS Registry Number.
InChI:InChI=1/C22H28N4O10S/c27-18(28)9-24(5-6-25(10-19(29)30)11-20(31)32)8-17(26(12-21(33)34)13-22(35)36)7-15-1-3-16(4-2-15)23-14-37/h1-4,17H,5-13H2,(H,27,28)(H,29,30)(H,31,32)(H,33,34)(H,35,36)/t17-/m0/s1
102650-30-6Relevant articles and documents
SYNTHESIS OF THERAPEUTIC AND DIAGNOSTIC DRUGS CENTERED ON REGIOSELECTIVE AND STEREOSELECTIVE RING OPENING OF AZIRIDINIUM IONS
-
, (2013/12/03)
Stereoselective and regioselective synthesis of compounds via nucleophilic ring opening reactions of aziridinium ions for use in stereoselective and regioselective synthesis of therapeutic and diagnostic compounds.
Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
-
, (2008/06/13)
New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site while minimizing the distribution of the compound to non-targeted organs or tissues is also disclosed.